Henry Schein (NASDAQ:HSIC)‘s stock had its “buy” rating reaffirmed by Piper Jaffray Companies in a note issued to investors on Wednesday, December 27th. They presently have a $78.00 target price on the stock. Piper Jaffray Companies’ price target indicates a potential upside of 4.22% from the company’s previous close.
A number of other brokerages have also recently commented on HSIC. Robert W. Baird set a $95.00 price objective on Henry Schein and gave the stock a “buy” rating in a research note on Thursday, October 19th. Stifel Nicolaus reduced their price objective on Henry Schein from $89.00 to $77.00 and set a “hold” rating on the stock in a research note on Tuesday, November 7th. Zacks Investment Research cut Henry Schein from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Craig Hallum upgraded Henry Schein from a “hold” rating to a “buy” rating in a research note on Tuesday, November 7th. Finally, UBS Group restated a “buy” rating on shares of Henry Schein in a research note on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $84.23.
Shares of Henry Schein (NASDAQ HSIC) opened at $74.84 on Wednesday. Henry Schein has a 1 year low of $65.28 and a 1 year high of $93.50. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.86 and a current ratio of 1.55. The stock has a market capitalization of $11,750.00, a PE ratio of 21.57, a price-to-earnings-growth ratio of 1.88 and a beta of 0.99.
Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.87 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.03). The firm had revenue of $3.16 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a net margin of 4.52% and a return on equity of 19.71%. Henry Schein’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $0.84 EPS. equities research analysts forecast that Henry Schein will post 3.6 EPS for the current year.
Henry Schein declared that its board has approved a stock buyback program on Monday, September 18th that allows the company to repurchase $400.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 6.3% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.
In related news, Director Barry J. Alperin sold 5,796 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $70.76, for a total value of $410,124.96. Following the transaction, the director now owns 48,172 shares in the company, valued at $3,408,650.72. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.19% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. YorkBridge Wealth Partners LLC raised its stake in Henry Schein by 5.2% during the second quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock valued at $104,000 after buying an additional 28 shares in the last quarter. Sun Life Financial INC raised its stake in Henry Schein by 8,185.7% during the second quarter. Sun Life Financial INC now owns 580 shares of the company’s stock valued at $106,000 after buying an additional 573 shares in the last quarter. Acrospire Investment Management LLC raised its stake in Henry Schein by 150.0% during the second quarter. Acrospire Investment Management LLC now owns 1,000 shares of the company’s stock valued at $183,000 after buying an additional 600 shares in the last quarter. Great Lakes Advisors LLC acquired a new stake in Henry Schein during the second quarter valued at approximately $205,000. Finally, Wesbanco Bank Inc. acquired a new stake in Henry Schein during the second quarter valued at approximately $205,000. Hedge funds and other institutional investors own 91.69% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/14/henry-schein-hsic-earns-buy-rating-from-piper-jaffray-companies.html.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.